• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
  • Overview of New "Don't Eat Me" Target CD24 Research Zhaoruijie/PharmaSources
    July 03, 2023
    Recently, Antengene Corporation announced that the Phase I clinical trial application (IND) of its global first anti-CD24 monoclonal antibody, ATG-031, had been approved by FDA.

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service